- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gain Therapeutics Inc (GANX)
Assess today's live Gain Therapeutics Inc (GANX) share price, performance and insights using our live NASDAQ: GANX stock exchange data.
Analyse the historical data and Gain Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Gain Therapeutics share price buy/sell indicators using real-time data (or discuss the Gain Therapeutics (GANX) stock price today with other investors in the Gain Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GANX share price (ISIN: US36269B1052) to enhance your trading decisions with our free investment tools and resources.
What Is the Gain Therapeutics Inc Share Price Today?
The Gain Therapeutics share price today is 3.080.
What Is the Stock Symbol for Gain Therapeutics Inc
The stock symbol (or 'ticker') for Gain Therapeutics Inc is "GANX."
What Stock Exchange Does Gain Therapeutics Inc Trade On?
Gain Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gain Therapeutics Inc a Good Stock to Buy?
Determining whether Gain Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Gain Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Gain Therapeutics share price buy/sell indicators using real-time data (or discuss the Gain Therapeutics (GANX) stock price today with other investors in the Gain Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GANX share price (ISIN: US36269B1052) to enhance your trading decisions with our free investment tools and resources.
What Is the Gain Therapeutics Inc Share Price Today?
The Gain Therapeutics share price today is 3.080.
What Is the Stock Symbol for Gain Therapeutics Inc
The stock symbol (or 'ticker') for Gain Therapeutics Inc is "GANX."
What Stock Exchange Does Gain Therapeutics Inc Trade On?
Gain Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Gain Therapeutics Inc a Good Stock to Buy?
Determining whether Gain Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.050
3.450
52 wk Range
1.410
4.340
GANX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.0503.450
52 wk Range
1.4104.340
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GANX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
7.600
Upside
+146.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Gain Therapeutics Company Profile
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Gain Therapeutics Inc SWOT Analysis
Innovative Approach | Gain Therapeutics pioneers protein misfolding treatments, targeting neurodegenerative diseases with proprietary allosteric binding site technology |
Financial Landscape | With $16.9M cash runway into 2025, GANX faces funding challenges. Analyst price targets range from $5 to $10, suggesting significant upside potential |
Clinical Milestones | Phase 1 trial progress for GT-02287 in GBA-Parkinson's disease sets stage for Phase 1b initiation in Q4 2024, crucial for validating technology |
Market Opportunity | Projected peak revenues of $800M by 2040 highlight vast potential in neurodegenerative treatments, balanced against fierce competition and development risks |
Compare GANX to Peers and Sector
Metrics to compare | GANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGANXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.1x | −3.2x | −0.6x | |
PEG Ratio | −0.15 | 0.09 | 0.00 | |
Price/Book | 20.0x | 3.4x | 2.6x | |
Price / LTM Sales | - | 391.3x | 3.2x | |
Upside (Analyst Target) | 159.7% | 61.7% | 41.8% | |
Fair Value Upside | Unlock | −10.4% | 5.1% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.600
(+146.75% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.15 / -0.15
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Gain Therapeutics (GANX) Share Price Today?
The live Gain Therapeutics share price today is 3.080
What Stock Exchange Does Gain Therapeutics (GANX) Trade On?
Gain Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Gain Therapeutics?
The stock symbol (also called a 'ticker') for Gain Therapeutics is "GANX."
What Is the Current Gain Therapeutics Market Cap?
As of today, Gain Therapeutics market capitalisation is 118.46M.
What Is Gain Therapeutics's (GANX) Earnings Per Share (TTM)?
The Gain Therapeutics EPS is currently -0.64 (Trailing Twelve Months).
When Is the Next Gain Therapeutics Earnings Date?
Gain Therapeutics's next earnings report will be released on 19 Mar 2026.
Is GANX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Gain Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Gain Therapeutics Stock Split?
Gain Therapeutics has split 0 times. (See the GANX stock split history page for full effective split date and price information.)
How Many Employees Does Gain Therapeutics Have?
Gain Therapeutics has 24 employees.
What is the current trading status of Gain Therapeutics (GANX)?
As of 24 Dec 2025, Gain Therapeutics (GANX) is trading at a price of 3.080, with a previous close of 3.190. The stock has fluctuated within a day range of 3.050 to 3.450, while its 52-week range spans from 1.410 to 4.340.
What Is Gain Therapeutics (GANX) Price Target According to Analysts?
The average 12-month price target for Gain Therapeutics is USD7.6, with a high estimate of USD10 and a low estimate of USD5. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +146.75% Upside potential.
What Is the GANX Premarket Price?
GANX's last pre-market stock price is 3.140. The pre-market share volume is 22,870.000, and the stock has decreased by -0.050, or -1.570%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.